GI
AMLX icon

GAMMA Investing’s Amylyx Pharmaceuticals AMLX Stock Holding History

GAMMA Investing’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78K Buy
433
+16
+4% +$247 ﹤0.01% 3307
2026
Q1 		$5.8K Buy
417
+150
+56% +$2.11K ﹤0.01% 3310
2025
Q4 		$3.23K Buy
267
+142
+114% +$1.93K ﹤0.01% 3450
2025
Q3 		$1.7K Buy
+125
New +$1.18K ﹤0.01% 3495
2024
Q2 		– Sell
-35
Closed -$99 – 3448
2024
Q1 		$99 Hold
35
– – ﹤0.01% 3285
2023
Q4 		$560 Buy
+35
New +$536 ﹤0.01% 2939

Other funds holding AMLX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PPWP
Premier Path Wealth Partners Madison, New Jersey $870M AUM 30% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return

GAMMA Investing's AMLX Position: Q2 2026 in Review

GAMMA Investing increased its Amylyx Pharmaceuticals (AMLX) stake by 3.8% in Q2 2026, buying an estimated $247 and bringing the position to 433 shares worth $7.78K. The position accounts for ﹤0.01% of the portfolio, ranked #3307.

GAMMA Investing first reported a position in AMLX in Q4 2023 and has held it in 6 quarters since. 10 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • GAMMA Investing held 433 shares of Amylyx Pharmaceuticals worth $7.78K as of Q2 2026.
  • GAMMA Investing bought 16 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $247.
  • Amylyx Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3307 holding.
  • GAMMA Investing first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • 10 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.